Clinical Trial Update: Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing effects of human milk oligosaccharides (HMOs) on gut microbiota, GI symptoms, mucosal immunity, and barrier function in patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• HMOs (human milk oligosaccharides)

Snippet

Sponsor: Glycom A/S | Conditions: Irritable Bowel Syndrome (IBS) | Phase 2 | Status: COMPLETED